Biophytis S.A. – NASDAQ:BPTS
Biophytis S.A. stock price monthly change
Biophytis S.A. stock price quarterly change
Biophytis S.A. stock price yearly change
Biophytis S.A. key metrics
Market Cap | 2.60M |
Enterprise value | 873.63K |
P/E | -0.2 |
EV/Sales | N/A |
EV/EBITDA | -0.04 |
Price/Sales | N/A |
Price/Book | 1.76 |
PEG ratio | -0.02 |
EPS | -68.44 |
Revenue | N/A |
EBITDA | -41.29M |
Income | -41.24M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBiophytis S.A. stock price history
Biophytis S.A. stock forecast
Biophytis S.A. financial statements
| Jun 2022 | 0 | -12.39M | |
|---|---|---|---|
| Dec 2022 | 0 | -11.81M | |
| Jun 2023 | 0 | -7.76M | |
| Dec 2023 | 0 | -9.26M |
| 2025 | 0 | -2.50M | |
|---|---|---|---|
| 2026 | 31.98M | 0 |
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 21987000 | 23.89M | 108.69% |
|---|---|---|---|
| Apr 2023 | 0 | 0 | |
| Jun 2023 | 14613000 | 17.96M | 122.95% |
| Dec 2023 | 11936000 | 15.84M | 132.78% |
| Jun 2022 | -10.94M | 333K | 6.37M |
|---|---|---|---|
| Dec 2022 | -8.70M | -350K | 420K |
| Jun 2023 | -8.40M | -777K | 3.93M |
| Dec 2023 | -4.92M | 1.14M | 3.55M |
Biophytis S.A. alternative data
| Aug 2023 | 24 |
|---|---|
| Sep 2023 | 24 |
| Oct 2023 | 24 |
| Nov 2023 | 26 |
| Dec 2023 | 26 |
| Jan 2024 | 26 |
| Feb 2024 | 26 |
| Mar 2024 | 26 |
| Apr 2024 | 26 |
| May 2024 | 22 |
| Jun 2024 | 22 |
| Jul 2024 | 22 |
Biophytis S.A. other data
| Patent |
|---|
Application Filling date: 23 Nov 2021 Issue date: 17 Mar 2022 |
Application Filling date: 23 Nov 2019 Issue date: 2 Jul 2020 |
Application Filling date: 26 Aug 2019 Issue date: 2 Apr 2020 |
| Insider | Compensation |
|---|---|
Mr. Stanislas Veillet Ph.D. (1965) Chairman & Chief Executive Officer | $422,580 |
-
When is Biophytis S.A.'s next earnings date?
Unfortunately, Biophytis S.A.'s (BPTS) next earnings date is currently unknown.
-
Does Biophytis S.A. pay dividends?
No, Biophytis S.A. does not pay dividends.
-
How much money does Biophytis S.A. make?
Biophytis S.A. has a market capitalization of 2.60M.
-
What is Biophytis S.A.'s stock symbol?
Biophytis S.A. is traded on the NASDAQ under the ticker symbol "BPTS".
-
What is Biophytis S.A.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Biophytis S.A.?
Shares of Biophytis S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Biophytis S.A.'s key executives?
Biophytis S.A.'s management team includes the following people:
- Mr. Stanislas Veillet Ph.D. Chairman & Chief Executive Officer(age: 60, pay: $422,580)
-
How many employees does Biophytis S.A. have?
As Jul 2024, Biophytis S.A. employs 22 workers, which is 15% less then previous quarter.
-
When Biophytis S.A. went public?
Biophytis S.A. is publicly traded company for more then 4 years since IPO on 10 Feb 2021.
-
What is Biophytis S.A.'s official website?
The official website for Biophytis S.A. is biophytis.com.
-
How can i contact Biophytis S.A.?
Biophytis S.A. can be reached via phone at +33 1 44 27 23 00.
Biophytis S.A. company profile:
Biophytis S.A.
biophytis.comNASDAQ
22
Biotechnology
Healthcare
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Paris, 75005
CIK: 0001768946
ISIN: US09076G2030
CUSIP: 09076G104
